JLE

Hépato-Gastro & Oncologie Digestive

MENU

Therapeutic management of metastatic colorectal cancer beyond the second-line Volume 26, issue 3, Mars 2019

Figures


  • Figure 1

  • Figure 2

Tables

Authors
1 Gustave Roussy, Département de médecine oncologique, Villejuif
2 CHU Pontchaillou, Service des maladies de l’appareil digestif, Rennes
3 Hôpital Cochin, Service de gastroentérologie et d’oncologie digestive, Paris
4 Hôpital Privé Jean Mermoz, Lyon
5 CHU de Nantes, Service d’hépatogastroentérologie et oncologie digestive, Nantes
* Correspondance

The improved survival of patients with metastatic colorectal cancer has led to an increasing number of patients able to receive third-line chemotherapy. In this situation, two orally administered drugs, regorafenib and trifluridine/tipiracil, have become therapeutic standards after having demonstrated a survival improvement as compared to best supportive care in randomised controlled trials. This review article presents the pharmacokinetic, efficacy and safety data for these two drugs, as well as current data on the search for predictive biomarkers of their efficacy, and other treatment options beyond the second line.

Licence This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License